Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Mar 26;10(2):201-204.
doi: 10.1093/jpids/piaa039.

Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis

Paul Krogstad  1 , Pearl Samson  2 , Edward P Acosta  3 , Jack Moye  4 , Ellen Townley  5 , Sarah Bradford  6 , Emily Brown  6 , Kayla Denson  7 , Bobbie Graham  7 , Laura Hovind  7 , Thucuma Sise  5 , Hedy Teppler  8 , Sisinyana Ruth Mathiba  9 , Lee Fairlie  10 , Jana L Winckler  11 , Gretchen Slade  12 , Tammy Meyers  13 ; International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1101 Team
Affiliations
Clinical Trial

Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis

Paul Krogstad et al. J Pediatric Infect Dis Soc. .

Abstract

Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to <2 years receiving concurrent rifampin to treat TB.

Clinical trials registration: NCT01751568.

Keywords: antiretroviral therapy; drug interactions; pediatrics; rifampin; tuberculosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Pharmacokinetic profiles of RAL in children receiving RAL concurrently with rifampin-based therapy for tuberculosis. The solid line represents the median value at each time point; the dashed lines display the 10th and 90th percentiles. Abbreviation: RAL, raltegravir.
See this image and copyright information in PMC

References

    1. World Health Organization. Global tuberculosis report 2018. World Health Organization. 2018. Available at: https://apps.who.int/iris/handle/10665/274453. Accessed November 20, 2019.
    1. World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. 2017. Available at: https://apps.who.int/iris/bitstream/handle/10665/255052/9789241550000-en.... Accessed November 20, 2019.
    1. Bhatt NB, Baudin E, Meggi B, et al. ; ANRS 12146/12214-CARINEMO Study Group . Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship. J Antimicrob Chemother 2015; 70:225–32. - PMC - PubMed
    1. Ren Y, Nuttall JJ, Eley BS, et al. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2009; 50:439–43. - PubMed
    1. Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009; 53:2852–6. - PMC - PubMed

Publication types

Associated data